Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Premier Oil Up As It Retains Guidance

Fri, 13th Mar 2020 10:58

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.

----------

FTSE 100 - WINNERS

----------

Royal Bank of Scotland Group and Lloyds Banking, up 6.1% and 4.8%, respectively. Citigroup raised both banks to Buy from Neutral.

----------

Barclays, up 5.4%. Citigroup raised the bank to Neutral from Sell.

----------

FTSE 100 - LOSERS

----------

TUI, down 8.0%. The tour operator has decided to halt pre-payments and suspend contracts with some of its hotels to survive the severe downturn in the travel industry caused by coronavirus, the Financial Times reported on Thursday. "We are in close contact with our hotel partners worldwide, jointly reviewing options for capacity management, to mitigate the impact for both Tui and its partners," the company told the newspaper. TUI also stated that it had frozen recruitment and was considering cutting staff hours. According to the FT, citing hoteliers in Spain and Greece, TUI was in talks with a number of operators to invoke "force majeure" clauses in contracts and temporarily stop payments.

----------

Carnival, down 3.2%. On Thursday, the company said its Princess Cruises division will voluntarily pause its global operations in response to the "unpredictable circumstances" evolving from the spread of Covid-19 virus. "In proactive response to the unpredictable circumstances evolving from the global spread of covid-19 and in an abundance of caution, Princess Cruises announced that it will voluntarily pause global operations of its 18 cruise ships for two months, impacting voyages departing March 12 to May 10," the travel leisure company said.

----------

FTSE 250 - WINNERS

----------

Premier Oil, up 77%. The oil company said it continues to perform well with production to the end of February of 76,600 barrels of oil equivalent a day. The company's annual output guidance stands between 70,000 to 75,000 barrels of oil equivalent a day, excluding the proposed UK acquisitions. With regards to the proposed acquisitions and extension to the company's credit facilities, the court hearing to sanction the creditor schemes of arrangement is scheduled to start on Tuesday next week, Premier noted. Elsewhere, Premier said it retains "significant" liquidity. It has unrestricted cash of USD135 million and undrawn facilities of USD330 million, as at the end of February. As well as maintaining liquidity, Premier is focused on managing its forward covenant position which could be hurt by the current oil price weakness, the company said.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Redx Pharma shares almost tripled to 13.88p from just 4.50p at the close on Thursday. The drug discovery company has received two separate acquisition offers, one from new shareholder Redmile Group and the second from former suitor Yesod Bio-Sciences. The company in February ended takeover talks with Yesod Bio-Sciences and instead inked a GBP26.3 million funding deal with two investors, US healthcare investor Redmile and Paris-based Sofinnova Partners. On Friday, however, Redx said Redmile upped its stake in the company to around 46%, forcing Redmile to make a mandatory takeover offer under UK takeover rules. As a result, Redmile made a mandatory cash offer for Redx shares not already owned at 15.5p each. Moulton Goodies was the largest shareholder of Redx, holding 42% as of January. Separately, Redx also announced a receipt of a further private approach from Yesod Bio-Sciences which may lead to a possible cash offer for the company at 15p per share.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Thor Mining, down 15%. The exploration and development company said its pretax loss widened to GBP479,000 in the six months to the end of 2019 compared to GBP406,000 loss reported a year ago. Thor did not generate any revenue in the period as it is currently developing its Kapunda copper project and Molyhil tungsten & molybdenum project, both located in Australia. Thor warned that copper prices moved in a range between USD5,000 per tonne and USD6,400 per tonne, with recent weakness potentially in a response to coronavirus disruption. The company also noted that tungsten pricing fell by 20% early in its financial half-year, but then recovered.

----------

GAN, down 14%. The internet gambling software supplier said internet gaming win in New Jersey was USD52.0 million in February, compared to USD31.7 million in the same month prior year, reflecting a year-on-year increase of 64%. Internet sports wagering gross revenues - after payouts - for the month of February were USD15.9 million, compared to USD12.9 million in February 2019, reflecting a year-on-year increase of 24%.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
10 Jul 2019 10:40

WINNERS & LOSERS SUMMARY: PageGroup Slumps After Profit Warning

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - LOSERS----------Micro Focus down

Read more
10 Jul 2019 09:41

Redx Pharma Shares Double After Jazz Pharmaceutical Deal

(Alliance News) - Redx Pharma PLC said Wednesday it has signed a definitive agreement with Nasdaq-listed Jazz Pharmaceuticals PLC to sell its pan-RAF inhibitor programme.Shares in the and a

Read more
10 Jun 2019 10:10

Redx Pharma Gets GBP2.5 Million Financing As Interim Loss Narrows

LONDON (Alliance News) - Redx Pharma PLC on Monday said its loss narrowed in the first half of its current financial year as it progresses on cancer and idiopathic pulmonary fibrosis drugs the and

Read more
10 Jun 2019 08:29

Redx Pharma narrows losses as RXC004 trials recommence

(Sharecast News) - Drug discovery and development company Redx Pharma published its interim results on Monday, revealing it had narrowed first-half losses as it progresses on cancer and idiopathic pulmonary fibrosis drugs development.

Read more
3 May 2019 14:07

Redx Pharma Exploring New Financing Options Despite Progress

LONDON (Alliance News) - Cancer and fibrosis-focused drug firm Redx Pharma PLC is "greatly encouraged" by talks over securing new financing.In November, Redx said it was looking a

Read more
3 May 2019 11:17

Redx Pharma extends cash runway into July

(Sharecast News) - Drug discovery and development company Redx Pharma updated the market on its ongoing plans to strengthen its balance sheet on Friday, with its board reiterating its commitment to strengthening the balance sheet in order to extend the cash runway beyond the second quarter of 2019, as it initially announced in November.

Read more
12 Feb 2019 13:42

Redx Pharma reveals promising data on 'ROCK2' compound

(Sharecast News) - Drug discovery and development company Redx Pharma announced promising preclinical efficacy data for its lead selective 'ROCK2' compound on Tuesday.

Read more
12 Feb 2019 09:45

Redx Pharma Sees Promising Results From Liver Disease Treatment

LONDON (Alliance News) - Redx Pharma PLC said Tuesday that preclinical efficacy data for its ROCK2 compound showed the product was able to have an impact on established fibrosis.Shares in a

Read more
6 Feb 2019 11:45

Redx Pharma Receives Oustanding Loan Amounts From Redag

LONDON (Alliance News) - Redx Pharma PLC on Wednesday said that it received a full cash repayment of GBP869,126, representing the outstanding amount of a loan made in 2014 to Redag Crop Protection

Read more
31 Jan 2019 11:03

Deinove Backs Out Of Anti-Infective NBTI Programme With Redx Pharma

LONDON (Alliance News) - Redx Pharma PLC on Thursday said French biotech firm Deinove SA will not exercise its option for Redx's novel bacterial topoisomerase inhibitor programme.Shares

Read more
31 Jan 2019 09:45

Deinove hands rights to NBTI programme back to Redx Pharma

(Sharecast News) - Drug discovery and development company Redx Pharma announced on Thursday that Deinove had decided not to exercise its option for Redx's 'Novel Bacterial Topoisomerase Inhibitor' (NBTI) programme.

Read more
30 Nov 2018 10:36

Redx Pharma Drug Candidate RXC006 To Be Developed As Fibrosis Drug

LONDON (Alliance News) - Drug developer Redx Pharma PLC said Friday its RXC006 drug candidate was able to suppress lung fibrosis in living organisms and will be developed as a treatment for in up

Read more
30 Nov 2018 10:31

Redx Pharma jumps as first data shows 'great potential' for fibrosis candidate

(Sharecast News) - Redx Pharma made gains on Friday after it said that pre-clinical data suggested that its RXC006 drug candidate has "great potential" as a treatment for fibrosis.

Read more
19 Nov 2018 13:07

Redx Pharma Posts Large Annual Loss, Appoints Astra Executive As CFO

LONDON (Alliance News) - Redx Pharma PLC on Monday posted a large loss due to the absence of a big exceptional disposal gain seen a year before and said that it has appointed James Mead as its new

Read more
19 Nov 2018 08:59

Redx Pharma swings to a loss following 'seminal' year

(Sharecast News) - A year after clambering out of administration, drug discovery and development outfit Redx Pharma swung to a loss but remains confident of making progress with a drug pipeline refocused on cancer and fibrosis.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.